Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Accept all cookies Reject all non-essential cookies

Cholesterol-lowering drug slows progression of eye disease in people with diabetes

The LENS trial has demonstrated that fenofibrate, a drug usually used to lower cholesterol, reduces the risk of progression of diabetic retinopathy by 27%. The results were announced today at the American Diabetes Association Scientific Sessions and published in NEJM Evidence.

Patient undergoing an eye examination © Getty Images (Zorica Nastasic)

Diabetes can cause damage to the small blood vessels at the back of the eye, a condition called diabetic retinopathy. Diabetic retinopathy is among the top five causes of visual loss worldwide and the only major cause to increase in recent decades.

Fenofibrate is a tablet that has been used to lower cholesterol for more than 30 years. Previous results from sub-studies of trials looking into treatments for heart disease had suggested that fenofibrate might be able to slow the progression of diabetic retinopathy but more conclusive results were needed.

Coordinated by Nuffield Department of Population Health, the LENS (Lowering Events in Non-proliferative retinopathy in Scotland) trial compared the effects of fenofibrate with a placebo (dummy tablet) on the progression of retinopathy in 1,151 adults with type 1 or type 2 diabetes in Scotland as part of the national routine diabetic eye screening programme. All of the participants had early to moderate diabetic retinopathy when they joined the trial.

Read the full story on the University of Oxford website

Similar stories

Oxford researchers support international response to Bundibugyo virus disease outbreak

Teams from across the University of Oxford are supporting the international response to the current Bundibugyo virus disease outbreak through interdisciplinary research spanning biomedical, public health and social and behavioural science.

Smoking and drinking exacerbate social inequalities in premature deaths in India

Study finds social inequality is a major predictor of premature death, even among people who neither smoke nor drink alcohol.

New Lancet review calls for urgent action to tackle the growing global threat of encephalitis

The review highlights encephalitis as an urgent global health challenge and calling for faster diagnosis, improved treatments, and strengthened prevention strategies to reduce death and disability worldwide.

Drought linked to 46% increase in sexual violence among adolescents in Southern Africa

Study reveals climate change is increasing risks to child safety.

Oxford launches interdisciplinary centre to advance women's mental health research globally

The University of Oxford is set to launch a new research centre dedicated to women’s mental health, bringing together expertise from medical and biological sciences with humanities for the first time.

New Lancet series shows how thousands of maternal deaths could be prevented each year

Every 12 minutes, somewhere in the world, a woman dies from excessive bleeding after birth (postpartum haemorrhage or PPH). Yet according to a new three-part Lancet Series, led by researchers from the University of Oxford, most of these deaths should never happen.